Lunai Bioworks Inc. (NasdaqCM: LNAI)
Health Care · Biotechnology · US
$0.68
-44.68% today · -93.0% 1Y
Lunai Bioworks Inc. (NasdaqCM: LNAI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.43M and employs 12 people.
Over the last twelve months the share price has lost 93.0%, trading between 0.66 and 13.28.
Tweenvest scores Lunai Bioworks Inc. across four factors: quality 37/100, value 44/100. Its strongest factor is value.
LNAI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.43M
- Revenue (TTM)
- $51.99K
- P/E
- —
- EPS
- -1.06
- Dividend yield
- —
- Beta (5Y)
- 0.35
- 52-week high
- $13.28
- 52-week low
- $0.66
- Avg volume (3M)
- —
- Shares outstanding
- 5.03M
- Employees
- 12
- Next earnings
- —
About Lunai Bioworks Inc.
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
- ISIN
- US29350E3027
- Listed since
- Sep 30, 2025
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PharmaCyte Biotech, Inc.NasdaqCM: PMCB | $3.65M | $0.34 | -15.88% |
| StageZero Life Sciences Ltd.TSXV: SZLS.H | $3.64M | CA$— | — |
| Tissue Repair LtdASX: TRP | $3.56M | AU$0.09 | -5.56% |
| Dermata Therapeutics, Inc.NasdaqCM: DRMA | $3.46M | $0.86 | -15.69% |
| Ernexa Therapeutics Inc.NasdaqCM: ERNA | $3.41M | $2.09 | -12.92% |
| National Graphite Corp.OTCPK: NGRC | $3.41M | $0.02 | +5.24% |
| Chosa Oncology ABNGM: CHOSA | $3.31M | Skr— | — |
| Affymax, Inc.OTCPK: AFFY | $3.10M | $0.04 | +2500.00% |
Figures last refreshed Oct 18, 2026.